Skip to content
The Nexus
DossierENTITY

enfortumab vedotin

Coverage of enfortumab vedotin in the Nexus archive.

Earliest in view: Jul 10 · 19:03 UTCMost recent: Jul 10 · 19:03 UTC
Co-mentioned in this coverage
FDAorganization1pembrolizumabtopic1Keytrudatopic1berahyaluronidase alfatopic1Keytruda Qlextopic1Padcevtopic1muscle-invasive bladder cancertopic1
Recent coverage
  • HEALTHJul 10 · 19:03 UTCMEDPAGE TODAY
    FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting

    The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with enfortumab vedotin (Padcev) as perioperative treatment for adults with muscle-invasive bladder cancer. The approval expands the use of a chemo-free therapy in a curative setting for this condition.

enfortumab vedotin · Dossier · The Nexus